ArticleHematology, transfusion and cell therapy2024
Bortezomib and low dose venetoclax therapy for relapsed/refractory B-cell acute lymphoblastic leukemia with IDH1 mutation.
Pronamee Borah et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.